Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Carcinoma, Hepatocellular 5Prostatic Neoplasms 3Liver Neoplasms 3Kidney Neoplasms 3Head and Neck Neoplasms 2Thyroid Neoplasms 1Sleep Apnea, Obstructive 1Sarcoma 1Rhinitis, Allergic, Seasonal 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Fibrosis 1Pulmonary Embolism 1Pulmonary Disease, Chronic Obstructive 1Ovarian Neoplasms 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Hypertension, Pulmonary 1Emphysema 1Cystic Fibrosis 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Bronchiectasis 1Asthma 1Asbestosis 1

Interventions

Magnetic Resonance Spectroscopy 4Specimen Handling 2High-Energy Shock Waves 2Biopsy 2perflutren 1olaparib 1exemestane 1entinostat 1abemaciclib 1X-Rays 1Tamoxifen 1Pharmacogenomic Testing 1Nivolumab 1Letrozole 1Ipilimumab 1Gonadotropin-Releasing Hormone 1Fulvestrant 1Fluorodeoxyglucose F18 1Estradiol 1CTLA-4 Antigen 1Blood Specimen Collection 1Anastrozole 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage III Breast Cancer AJCC v8 × perflutren × Clear all
NCT04715958 2026-04-06

SHAPE Neoadjuvant Chemotherapy Response

Thomas Jefferson University

Phase 2/3 Recruiting
200 enrolled
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡